138 related articles for article (PubMed ID: 15517874)
1. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu X; Powlas J; Shi Y; Oleksijew AX; Shoemaker AR; De Jong R; Oltersdorf T; Giranda VL; Luo Y
Anticancer Res; 2004; 24(5A):2697-704. PubMed ID: 15517874
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
3. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
Yang L; Dan HC; Sun M; Liu Q; Sun XM; Feldman RI; Hamilton AD; Polokoff M; Nicosia SV; Herlyn M; Sebti SM; Cheng JQ
Cancer Res; 2004 Jul; 64(13):4394-9. PubMed ID: 15231645
[TBL] [Abstract][Full Text] [Related]
4. Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL(male symbol)1 cells.
Tanino M; Matsuo M; Uenaka A; Tsukuda K; Ouchida M; Nakayama E; Shimizu K
Mol Carcinog; 1999 Dec; 26(4):286-97. PubMed ID: 10569805
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
6. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
Tang HJ; Jin X; Wang S; Yang D; Cao Y; Chen J; Gossett DR; Lin J
Gynecol Oncol; 2006 Feb; 100(2):308-17. PubMed ID: 16209885
[TBL] [Abstract][Full Text] [Related]
7. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S
Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254
[TBL] [Abstract][Full Text] [Related]
8. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells.
Park BK; Zeng X; Glazer RI
Cancer Res; 2001 Oct; 61(20):7647-53. PubMed ID: 11606407
[TBL] [Abstract][Full Text] [Related]
9. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Georgakis GV; Younes A
Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
[TBL] [Abstract][Full Text] [Related]
10. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation.
Kim MJ; Byun JY; Yun CH; Park IC; Lee KH; Lee SJ
Mol Cancer Res; 2008 Dec; 6(12):1872-80. PubMed ID: 19074832
[TBL] [Abstract][Full Text] [Related]
11. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
Vanderweele DJ; Rudin CM
Mol Cancer Res; 2005 Nov; 3(11):635-44. PubMed ID: 16317089
[TBL] [Abstract][Full Text] [Related]
14. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
15. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.
Aoki H; Takada Y; Kondo S; Sawaya R; Aggarwal BB; Kondo Y
Mol Pharmacol; 2007 Jul; 72(1):29-39. PubMed ID: 17395690
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
17. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts.
Yen ML; Su JL; Chien CL; Tseng KW; Yang CY; Chen WF; Chang CC; Kuo ML
Mol Pharmacol; 2005 Oct; 68(4):1061-73. PubMed ID: 15998873
[TBL] [Abstract][Full Text] [Related]
18. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
Mazières J; Tillement V; Allal C; Clanet C; Bobin L; Chen Z; Sebti SM; Favre G; Pradines A
Exp Cell Res; 2005 Apr; 304(2):354-64. PubMed ID: 15748883
[TBL] [Abstract][Full Text] [Related]
19. Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo.
Karnauskas R; Niu Q; Talapatra S; Plas DR; Greene ME; Crispino JD; Rudin CM
Oncogene; 2003 Feb; 22(5):688-98. PubMed ID: 12569361
[TBL] [Abstract][Full Text] [Related]
20. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.
Liu ZJ; Xiao M; Balint K; Smalley KS; Brafford P; Qiu R; Pinnix CC; Li X; Herlyn M
Cancer Res; 2006 Apr; 66(8):4182-90. PubMed ID: 16618740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
